Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply.
Publication
, Journal Article
Armstrong, PW; Anstrom, KJ; O'Connor, CM; VICTORIA Study Group
Published in: N Engl J Med
October 8, 2020
Duke Scholars
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
October 8, 2020
Volume
383
Issue
15
Start / End Page
1497 / 1498
Location
United States
Related Subject Headings
- Stroke Volume
- Pyrimidines
- Humans
- Heterocyclic Compounds, 2-Ring
- Heart Failure
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, P. W., Anstrom, K. J., O’Connor, C. M., & VICTORIA Study Group. (2020). Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply. N Engl J Med, 383(15), 1497–1498. https://doi.org/10.1056/NEJMc2027731
Armstrong, Paul W., Kevin J. Anstrom, Christopher M. O’Connor, and VICTORIA Study Group. “Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply.” N Engl J Med 383, no. 15 (October 8, 2020): 1497–98. https://doi.org/10.1056/NEJMc2027731.
Armstrong PW, Anstrom KJ, O’Connor CM, VICTORIA Study Group. Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply. N Engl J Med. 2020 Oct 8;383(15):1497–8.
Armstrong, Paul W., et al. “Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply.” N Engl J Med, vol. 383, no. 15, Oct. 2020, pp. 1497–98. Pubmed, doi:10.1056/NEJMc2027731.
Armstrong PW, Anstrom KJ, O’Connor CM, VICTORIA Study Group. Vericiguat in Heart Failure with Reduced Ejection Fraction. Reply. N Engl J Med. 2020 Oct 8;383(15):1497–1498.
Published In
N Engl J Med
DOI
EISSN
1533-4406
Publication Date
October 8, 2020
Volume
383
Issue
15
Start / End Page
1497 / 1498
Location
United States
Related Subject Headings
- Stroke Volume
- Pyrimidines
- Humans
- Heterocyclic Compounds, 2-Ring
- Heart Failure
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences